Psoriatic Arthritis

Continuous improvement across all MDA domains was demonstrated over the 100-week timeframe, with approximately 70% of patients achieving near remission in swollen joint count, enthesitis, and the Psoriasis Area and Severity Index (PASI).

At the 6-month mark, between 73.2% to 78.6% of Canadian patients with psoriatic arthritis reported pain.

b/tsDMARD treatment led to a mean relative improvement of 41% for total work productivity in patients with psoriatic arthritis.

Results revealed a consistent safety profile with low rates of discontinuation and no increase in adverse events with prolonged treatment exposure in patients treated with ixekizumab.

The findings of this post-hoc analysis suggest a need for follow-up studies assessing and comparing JAK inhibition impact on the development of enthesitis.

Among other manifestations, patients with PsA and neuropathic pain tended to have higher leptin levels, poor sleep quality, and greater levels of fatigue.

This retrospective cohort study suggests the potential benefits of greater use of screening, though additional research on these predictive factors may be necessary as well.

The ACR's Psoriatic Arthritis Guidelines provides comprehensive recommendations for managing active psoriatic arthritis and aims to assist clinicians and patients in making informed decisions tailored to individual situations. Test your knowledge with this quiz.

These data on the success of twice-daily, 5 and 10 mg doses of tofacitinib may help inform clinicians in their practice as well as the health community in general.

These findings on both remission and low disease activity suggest that some individuals in routine clinical practice may see benefits after extending treatment with etanercept past 12 weeks.

Patients with rheumatic disease treated with biosimilar SDZ ETN reported high treatment persistence at month 12 as well as comparable safety and efficacy.

Patients with inflammatory arthritis demonstrated significantly increased odds of depression and anxiety health care encounters and use of anxiolytics and antidepressants.

Angus Worthing, MD, discusses the recent developments in rheumatology and his predictions for the future of treatment moving into 2024 and beyond.

In a new study, 31.9% of individuals with osteoporosis had depressive symptoms and 10% had probable depression.

Results showed no differences regarding safety, although the biosimilar group had slightly more discontinuations due to inefficacy.

BLA submission was based on data from phase 3 clinical trials in which DMB-3115 showed no clinically meaningful differences compared with the reference product for the treatment of plaque psoriasis.

In this discussion with Dr. Mease at ACR 2023, he covers findings on an assessment tool known as the PsA-5Ts for patients with psoriatic arthritis.

This interview segment with Dr. Mease featured a discussion about data presented at ACR 2023 on guselkumab and patients with psoriatic arthritis.

In a new study, patients with psoriasis had a 39.46% prevalence of being overweight and 37.41% prevalence of obesity—83.56% patients also dismissed the importance of having healthy balanced eating habits.

This segment of Dr. Kivitz’s interview at ACR 2023 featured a discussion about future research on TAK-279 as well as general outlook on the field for psoriatic arthritis.

During this interview, Dr. Kivitz explained the background and key findings of his team’s research on TAK-279, a selective oral TYK2 inhibitor.

At the 7-month mark, multivariate analysis revealed patients with psoriasis aged ≥65 years reported a significantly better response to tildrakizumab.

Syndesmophyte development was 4 times more probable when patients had a clinical or radiographic description of axial involvement combined with elevated C-reactive protein.

The FDA has expanded the approval of abatacept (Orencia) for the treatment of active psoriatic arthritis in patients aged 2 years and older.

Ruth Napier, PhD, discusses her study revealing the crucial role the biomarker Card9 plays in the pathogenesis of ankylosing spondylitis.

Results from a large observational retrospective cohort of ≥500 patients with PsA show relatively low drug persistence of apremilast, an oral PDE4 inhibitor.

24-week results from the UPREAL show higher efficacy of upadacitinib among males with PsA, bio-naïve patients, and those with elevated baseline C-reactive protein.

Many studies support the finding that biologic therapy reduces the presence of psoriatic arthritis—or the risk of developing arthritis in psoriatic patients—but other research suggest the opposite.

Esme Fuller-Thomson, PhD, MSW, discusses findings from her recent study about psychiatric disorders and mental health in patients with arthritis.

A cross-sectional study of survey data shows more than 50% of psoriasis and over 60% of psoriatic arthritis patients have depressive symptoms, with results drawing a link between functional impairment and the likelihood of depressive symptoms.